Latest Vascular endothelial growth factor Stories
INDIANAPOLIS, Oct. 15, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the REGARD trial, a Phase III study of ramucirumab (IMC-1121B) in patients with metastatic gastric cancer, met its primary endpoint of improved overall survival and also showed prolonged progression-free survival. This trial is the first Phase III data read-out for ramucirumab. The REGARD trial compared ramucirumab and best supportive care to placebo and best supportive care as a...
INDIANAPOLIS, Sept. 29, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data from two Phase II ramucirumab (IMC-1121B) trials in patients with non-small cell lung cancer (NSCLC). Results were presented today during the Lung Cancer - Metastatic Poster Session at the ESMO 2012 Congress (European Society for Medical Oncology), 1:00 p.m. - 2:00 p.m. CET, in Vienna, Austria. Interim data for a study in chemotherapy-naive patients with advanced NSCLC treated...
TARRYTOWN, N.Y., Sept. 28, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that EYLEA(®) (aflibercept) Injection has received approval for the treatment of patients with neovascular age-related macular degeneration (wet AMD) from the Japanese Ministry of Health, Labour and Welfare (MHLW). In Japan, EYLEA treatment is initiated with one 2 milligram (mg) intravitreal injection per month for three consecutive months (treatment initiation)....
MELBOURNE, Australia, Sept. 26, 2012 /PRNewswire/ -- CSL Limited has developed a new drug candidate that is able to prevent the development of type 2 diabetes and reverse its progression in animal models of the disease. The drug candidate blocks signalling by a protein known as Vascular Endothelial Growth Factor B (VEGF-B) and this prevents fat from accumulating in the "wrong" places, such as in muscles and in the heart. As a result, cells within these tissues are once again able to...
NEW YORK, Sept. 24, 2012 /PRNewswire/ -- Ohr Pharmaceutical (OTCBB: OHRP-News) today announced the initiation of a Phase II clinical trial to evaluate the efficacy and safety of Squalamine Eye Drops for the treatment of the wet form of age-related macular degeneration ("wet-AMD"). The randomized, double blind, placebo controlled study will enroll patients at twenty one ophthalmology treatment centers across the United States. Interim results are expected in the fourth quarter of...
TARRYTOWN, N.Y., Sept. 21, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA(®) (aflibercept) Injection for the treatment of Macular Edema following Central Retinal Vein Occlusion (CRVO). The recommended dose for EYLEA is 2 milligrams (mg) every 4 weeks (monthly). "This second U.S. approval for EYLEA provides physicians and patients with a new treatment option for the treatment of...
TARRYTOWN, N.Y., Sept. 21, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that EYLEA(®) (aflibercept) Injection has been recommended for approval by the European Committee for Medicinal Products for Human Use (CHMP) for the treatment of patients with neovascular (wet) age-related macular degeneration (wet AMD). The decision of the European Commission on approval is expected in the fourth quarter of 2012. "We are pleased with the positive...
High blood pressure is responsible for many cardiovascular diseases that are the leading cause of death in industrialized countries. High salt intake has long been considered a risk factor, but not every type of high blood pressure is associated with high salt intake. This has puzzled scientists for a long time. However, new findings by Professor Jens Titze (Vanderbilt University, Nashville, Tennessee, USA and the University of Erlangen) now point to previously unknown mechanisms....
ROCKVILLE, Md., Sept. 6, 2012 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today the publication of an article by Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute in Boston, entitled "ENMD-2076, an Oral Inhibitor of Angiogenic and Proliferation Kinases, Has Activity in Recurrent, Platinum Resistant Ovarian Cancer," in the European Journal of Cancer. (Logo:...
IRVINE, Calif., Aug. 28, 2012 /PRNewswire/ -- GeneTex, Inc., a leading manufacturer of antibodies, has announced that they will be launching a new antibody against HIF1a (hypoxia-inducible factor 1alpha). (Photo: http://photos.prnewswire.com/prnh/20120828/AQ63427) (Logo: http://photos.prnewswire.com/prnh/20111129/LA13485LOGO-b) Hypoxia, a physiological state characterized by reduced oxygen levels, impacts metabolism, angiogenesis, vasodilation and erythropoiesis through the...
